Peregrine Pharmaceuticals (PPHM) announced the results from its internal review of discrepancies from its Phase II placebo-controlled trial of bavituximab in second-line non-small cell lung cancer in 121 patients Monday morning. The review indicates that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.
Peregrine Pharmaceuticals gapped open higher Monday and climbed throughout the first 2 hours of trade. Shares finished up by 1.08 at $2.43, with volume at over a 3-month high. The stock surged to its highest level since late September.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org